Basic Statistics on the Venereal Disease Problem in the United States

VD FACT SHEET 1966

Twenty-third Revision

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE BUREAU OF DISEASE PREVENTION AND ENVIRONMENTAL CONTROL NATIONAL COMMUNICABLE DISEASE CENTER Atlanta, Georgia 30333

Contents

	Page
Introduction	1
Incidence	2
Costs of Uncontrolled Syphilis	3-4
Reported Mortality and Insanity Due to Syphilis	5-6
Reported Cases of Venereal Diseases	7-14
All Stages of Syphilis and Gonorrhea, Cases and Rates, 1919-1940 .	(8)
Stages of Disease, Cases and Rates, 1941-1966	(9)
Stages of Disease, Cases, Race, Sex, Rates, 1962-1966	(10)
Congenital Syphilis, Age, 1963-1966	(11)
Infectious Syphilis and Gonorrhea, Age, Rates, 1956, 1961-1965	(12-13)
Each State, Selected Stages of Disease, Cases, Rates, 1966	(14)
Health Department Casefinding Activities	15
Treatment of Syphilis	16-17
Treatment of Gonorrhea	17-18
Penicillin Reactions	18

.

Introduction

The VD Fact Sheet is intended as a handy source of basic statistics on the venereal diseases in the United States. In this booklet, public health specialists, students, physicians, and other persons interested in medical data will find venereal diseases measured by incidence and prevalence. The general public will find tables showing the costs of uncontrolled venereal disease and the frequency of psychoses and deaths from syphilis. While the results of case-finding are measured in terms of cases reported, the actual amount of casefinding effort is seen in the volume of diagnostic examinations and epidemiologic activity. As there is no agent for immunizing the population, finding and treating cases continues to be the only feasible means of controlling venereal disease.

Facts on these aspects of the venereal disease problem and program are presented in the text and tables which follow. The information is current as of the date of publication, and it supersedes any previously published data. Where no source is cited, the data presented are based on the statistics collected by the Venereal Disease Program of the National Communicable Disease Center, or upon estimates made by the Program. Where data are indicated as being for "fiscal years," the period runs from July 1 of the previous year through June 30 of the year indicated on the table. Rates per 100,000 population shown in this Fact Sheet are based on appropriate population estimates obtained from the Bureau of the Census.

Incidence

The incidence of syphilis is defined as the number of new cases occurring in a given area within a specified period of time, usually a year.

Since the symptoms of primary and secondary syphilis appear soon after the disease is acquired, the number of primary and secondary cases occurring in the population within a given period of time would be the same as the incidence of syphilis.

Cases of primary and secondary syphilis are reportable by law in all of the 50 States and the District of Columbia. In the fiscal year ending June 30, 1966, physicians and clinics in the United States reported 22,473 cases to State or local departments of health. But the number of cases reported understates actual incidence for two reasons:

- 1. Not all cases are diagnosed, and
- 2. Not all diagnosed cases are reported.

In July 1962, the American Social Health Association, in cooperation with the American Medical Association, the National Medical Association, and the American Osteopathic Association sent a questionnaire to every private physician in the United States. One of the questions asked was "How many new cases of primary and secondary (infectious) syphilis did you treat between April 1 and June 30, 1962?"

One hundred and thirty-one thousand two hundred and forty-five responding physicians indicated they treated 13,930 cases of infectious syphilis during these three months (an estimate of 55,720 cases for the year 1962). These 55,720 cases plus 13,769 cases of infectious syphilis treated in 1962 by public clinics (not included in the survey) total an estimated 69,489 newly acquired cases of syphilis treated. Actually, 69,489 cases can be considered minimum incidence since it does not include cases treated by physicians who failed to respond to the survey nor cases occurring but not detected during the year. This estimate is presented only to show that the actual incidence of syphilis is much higher than reported new cases. In fact, if one considers that at least half of the cases occurring are not detected until the late or latent stages of disease, then the actual annual incidence of syphilis would be at least twice the estimated 69,489 cases treated in 1962.

Costs of Uncontrolled Syphilis

The statistics presented in Table 1 (next page) indicate the toll imposed by syphilis upon the manpower and economy of the country.

The estimate of man-years of disability for institutionalization of the syphilitic insane is based on the total number of patients in mental institutions and upon the proportion of those diagnosed as having syphilitic psychoses. Patients in State, county, and Veterans Administration hospitals for the permanent care of the insane are included.

The cost of maintenance is based upon the number of patients with syphilitic psychoses in tax supported institutions and upon the average per patient maintenance cost. Approximately three percent of patients with syphilitic psychoses are maintained in private institutions and these have not been included in this report.

Disability attributed to cardiovascular syphilis and to locomotor ataxia is based on conservative estimates of the prevalence of these late manifestations of syphilis.

The loss of life expectancy indicates the loss of future years of life for persons dying of syphilis in 1964. It is based on the expected years of life remaining to persons of that age, color and sex. The loss of income is based on projected earnings of these persons for the productive years of life lost to age 65. The estimated earnings are based on the median total money income rate for adults for 1964.

While disabilities and deaths from syphilis have been diminishing in recent years, costs and losses per case have been rising. As a result, total costs and income losses from syphilitic disabilities and deaths remain high compared to previous estimates.

On the basis of findings of research conducted in Macon County, Alabama, it has been estimated that the life expectancy of a Negro male between the ages of 25 and 60 years, infected with syphilis and receiving no appreciable treatment for his infection, is reduced by about 17 percent.*

^{*}Shafer, J.K.; Usilton, Lida J.; Gleeson, Geraldine A.: Untreated Syphilis in the Male Negro: A prospective study of the effect on life expectancy. Public Health Reports, 69:654-690, July 1954. Milbank Memorial Fund Quarterly, 32:262-274, July 1954.

ESTIMATED ANNUAL COSTS OF UNCONTROLLED SYPHILIS UNITED STATES, 1964*

MAN-YEARS OF SYPHILIS DISABILITY PER YEAR	
Institutionalization for syphilitic insanity	17,100
Disability from cardiovascular syphilis including aneurysm	8,100
Disability from tabes dorsalis	100
Disability from syphilitic blindness	6,000
ECONOMIC COSTS OF SYPHILITIC PSYCHOSES AND SYPHILITIC BLINDNESS PER YEAR	
Maintenance of patients with syphilitic psychoses • • • • • • • • • • • • •	\$46,424,000
Compensation to syphilitic blind	\$ 6,192,000
LOSS OF LIFE EXPECTANCY FROM DEATHS DUE TO SYPHILIS IN MAN-YEARS	
White males	18,849
White females	8,462
Non-white males	8,422
Non-white females	5,056
Total population	40,789
LOSS OF INCOME TO AGE 65 AT 1964 MEDIAN TOTAL MONEY INCOME RATE	\$41,158,000

*Estimates based on most recent year (1964) for which data is available.

Reported Mortality and Insanity Due to Syphilis

Mortality statistics are processed and tabulated in the National Center for Health Statistics (NCHS) from microfilm copies of the original certificates filed with State or local registrars. Mortality rates for syphilis are calculated by dividing the number of deaths in a given year by the population for that year and multiplying by 100,000 (rate per 100,000 population).

The infant mortality rate for syphilis for a given year is obtained by dividing the number of deaths due to syphilis among children under one year of age by the number of live births in the year multiplied by 10,000 (rate per 10,000 live births).

Since deaths from syphilis represent casefinding and treatment failures, mortality due to syphilis may be considered an inverse measure of the success of the syphilis control program.

It has been the practice since 1900 to revise the International Lists of Diseases and Causes of Death about every 10 years to keep abreast of medical progress. These revisions have at times affected the continuity of syphilis mortality statistics. "The Sixth Revision of the International Lists of Causes of Death," which became effective in 1949, reduced reported syphilis deaths by about 26 percent. In "The Seventh Revision of the International Lists of Causes of Death," which was published in 1955 and became effective beginning January 1958, an increase of 3.3 percent for syphilis and its sequelae occurred by reason of a change in interpretation of "aneurysm of the aorta" reported in a sequence involving arteriosclerosis of sites other than the aorta. It should be noted, however, that the interpretation of such sequences reverted in 1959 to that used with the Sixth Revision. Mortality rates given in this FACT SHEET have been adjusted to the basis of the Seventh Revision. No adjustment was made for infant mortality since it was affected very little by changes in the Seventh Revision.

Insanity due to syphilis is measured by the rate of first admissions to mental hospitals because of syphilis. Excluded are first admissions to psychopathic hospitals which provide only temporary care, and admissions to Veterans Administration facilities. The number of admissions is obtained from "Patients in Mental Institutions" published by the National Institute of Mental Health. Since only first admissions are included in the rate, the figures over a period of years represent a measure of the trend of incidence of syphilitic insanity.

Data on mortality and insanity due to syphilis are presented in Table 2 (next page).

2	
ABLE	
[1	

REPORTED MORTALITY AND INSANITY DUE TO SYPHILIS UNITED STATES SELECTED YEARS 1940-1966

		SYPHILIS MORTALITY*	MORTALITY	*	INFANT	INFANT MORTALITY DUE TO SYPHILIS	Y DUE TO	SYPHILIS	MENTAL DUE TO	MENTAL HOSPITALS DUE TO SYPHILIS
	Total Number	Rate Total	<u>Per 100,000</u> <u>White</u> N	000 Pop. Nonwhite	Total Number	Rate Per Total	10,000 L White	Live Births Nonwhite	Rate/100,00	
1940	14.064	10.7	7.3	40.2	1.251	5,30	2.50	25.20	7,694	6.1
1945	0,40	7.9		• •	0	2.50	1.07		, 66 9	5 • 5
1950	7,568	5.0		0	201	.57	.24	2.5	3,751	•
1951	6,274	4.1	3.0	•	129	.34	.12	1.73	਼ੁ	2.1
1952	•	•	2.7	11.4	92	.24	.10	1.14	2,602	1.8
1953	5,273	3.3	2.4	10.9	56	.14	.04	.77	2,360	1.5
1954	4,835	3.0	2.3	9.2	43	.11	.03	.54	2,145	1.3
1955	•	2.4	1.7	•	34	• 08	.03	.41	1,663	1.0
1956	•	•	1.7	7.1	30	.06	.02	.31	1,373	æ.
1957	•	2.2	1.7	٠	20	.06	.05	.16	1,307	ø.
1958	•	2.0	1.5	6.4	29	.07	.02	.36	1,321	.6
1959	•	1.7	1.3	4.9	19	.06	.02	.23	774	.4
1960	•	1.6	1.3	4.5	30	.07	.04	.24	742	4.
1961	2,850	1.6	1.2	4.5	20	.05	.02	.18	639	. .
1962	•	1.5	1.2	٠	29	.07	.02	.33	452	• 2
1963	•	1.4	1.1	3.5	19	.07	.01	.22	312	.1
1964	•	1.4	1.1	3.2	20	.05	.02	.18	260	.1
1965***	2,520	1.3	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
1966****	•	1.3	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Does not include admissions to Veterans Administration and psychopathic hospitals; rate based on population of Seventh Revision, International Lists of Causes of Death, 1955; see Mortality, Page 5 for explanation. area reporting. ** ×

*** Estimated.

Source: Mortality and Natality Data, National Vital Statistics Division; First Admissions to Mental Hospitals, National Institute of Mental Health; Rates based on population estimates of the Bureau of the Census.

Reported Cases of Venereal Disease

All States require that each case of syphilis and gonorrhea which comes to medical attention must be reported to the State or local health officer. The other venereal diseases are also reportable in most States. Every three months, each State submits to the Public Health Service a statistical summary of cases reported during the quarter. All cases not previously reported in the State, regardless of duration of infection or treatment status, are to be counted in the statistical report of cases. Reported morbidity, as reported cases are sometimes called, indicates the volume of successful casefinding.

The trend of reported cases or case rates of early syphilis over a period of years may be indicative of incidence trends if no significant changes in casefinding efforts or completeness of case reporting have occurred. Similarly, the trend of reported cases of syphilis in all stages of disease can be interpreted as indicative of prevalence trends subject to the limitations imposed by changes in casefinding efforts and completeness of case reporting. For these reasons, trends in reported cases and rates must be interpreted with caution since changes in casefinding efforts and completeness of case reporting are reflected in morbidity data just as much as changes in disease incidence and prevalence.

Reported venereal disease cases and rates are shown in Tables 3 through 9. Of particular recent interest is the slight decrease in primary and secondary syphilis cases which occurred in Fiscal Year 1966 after eight successive years of increases, the increases measuring as much as 50 percent per year in the years 1960 and 1961.

The differences in reported cases and rates between color groups as shown in Table 5 may be biased because nonwhites tend to utilize public diagnostic and treatment facilities where reporting is complete and whites tend to seek treatment at private diagnostic facilities where reporting is not complete.

The trend of reported cases of congenital syphilis by age is shown in Table 6, and Tables 7 and 8 show age specific cases and rates by color and sex for primary and secondary syphilis and for gonorrhea.

CASES OF SYPHILIS AND GONORRHEA REPORTED TO THE PUBLIC HEALTH SERVICE BY STATE HEALTH DEPARTMENTS, AND RATES PER 100,000 POPULATION All Reporting Areas in United States Fiscal Years 1919-1940

Fiscal	ALL STAGES O	F SYPHILIS	GONORR	HEA
Year	Cases	Rates	Cases	Rates
1919	100,466	113.2	131,193	147.8
1920	142,869	145.3	172,387	175.4
1921	184,090	172.3	189,927	177.7
1922	171,824	157.7	152,959	140.4
1923	172,258	156.2	156,826	142.2
1924	194,936	174.2	161,676	144.5
1925	201,692	181.2	166,208	149.3
1926	205,595	196.1	164,808	157.2
1927	196,457	171.9	160,793	140.7
1928	185,437	174.2	147,219	138.3
1929	195,559	169.2	156,544	135.4
1930	213,309	185.4	155,875	135.5
1931	229,720	197.4	155,895	134.0
1932	242,128	208.2	154,051	132.5
1933	238,656	193.4	149,823	121.4
1934	231,129	186.7	153,542	124.1
1935	255,856	205.6	162,763	130.8
1936	267,717	212.6	163,465	129.8
1937	336,258	264.3	182,460	143.4
1938	480,140	372.0	198,439	153.8
1939	478,738	367.1	182,314	139.8
1940	472,900	359.7	175,841	133.8

NOTE: Beginning in 1939, all States are included in the reporting area.

CASES OF VENEREAL DISEASE REPORTED TO THE PUBLIC HEALTH SERVICE BY STATE HEALTH DEPARTMENTS, AND RATES PER 100,000 POPULATION Fiscal Years 1941-1966 (Known Military Cases Excluded) United States

REPORTED VENEREAL DISEASE CASES AND CASE RATES PER 100,000 POPULATION BY COLOR AND SEX Fiscal Years 1962-1966 (Known Military Cases Excluded) UNITED STATES

	Ficcal			Total						White	e					Nonwhite	ite		
Disease, Stage	Year	Total		Male		Female	01	Total	al	Male		Female	e	Tota!	al	Male	0	Female	le
		Cases	Rates	Cases	Rates	Cases R	Rates	Cases	Rates	Cases	Rates	Cases	Rates	Cases	Rates	Cases	Rates	Cases	Rates
All Stages of Syphilis*	1962 1963 1964 1965 1966	124,188 128,450 118,247 113,018 110,128	68.1 6933 62.9 57.1	68,974 70,530 65,291 62,388 60,935	77.1 78.1 71.4 67.9 65.0	55,21 4 57,920 52,956 50,630 49,193	59.5 60.9 52.0 49.5	53,108 55,434 50,015 44,643 41,269	32.9 33.9 30.1 26.7 24.3	31,798 32,499 29,454 26,479 24,239	40.0 40.7 36.5 32.6 29.3	21,310 22,935 20,561 18,164 17,030	26.0 27.3 24.1 21.3 19.5	71,080 73,016 68,232 68,375 68,859	340.4 337.9 310.0 304.9 299.9	37,176 38,031 35,909 36,696	367.5 364.7 338.0 332.5 243.9	33,904 34,985 32,395 32,166 32,163	314.9 312.9 284.0 279.2 270.2
Primary and Secondary Syphilis	1962 1963 1964 1965 1966	20,084 22,085 22,733 23,250 22,473	11.0 11.9 12.1 12.3 11.6	13,214 14,074 14,349 14,351 13,730	14.8 15.6 15.7 15.6 14.6	6,870 7,971 8,384 8,899 8,743	8.4 8.4 8.1 8.1	6,149 6,128 6,153 5,571 4,736	23.3 23.8 23.3 23.3 23.3 23.3 23.3 23.3	4,972 4,800 4,815 4,213 3,567	6.0 4.2 5.2	1,177 1,328 1,338 1,358 1,358	1.4 1.5 1.5 1.3	13,935 15,917 16,580 17,679 17,737	66.7 73.7 75.3 78.8 77.2	8,242 9,274 9,534 10,138 10,163	81.5 88.9 89.9 93.9 67.6	5,693 6,643 7,046 7,541 7,574	52.9 59.4 61.7 64.8 63.6
Early Latent Syphilis	1962 1963 1964 1965 1966	19,924 18,683 18,104 17,315 16,974	10.9 9.6 9.1 8.8	10,800 10,010 9,880 9,522 9,729	12.1 11.0 10.8 10.4 10.4	9,124 8,673 8,224 7,245 7,245	9.9 8.5 7.3 0.5	6,749 6,282 5,614 4,695 4,399	4.2 3.4 2.8 2.6	4,347 3,965 3,652 3,179 2,963	3.9 5.6 3.9 5.6	2,402 2,317 1,962 1,516 1,436	2.9 2.3 1.6	13,175 12,401 12,490 12,490 12,575	63.1 57.4 56.3 54.8 54.8	6,453 6,045 6,228 6,343 6,766	63.8 58.0 58.7 58.7 44.9	6,722 6,356 6,262 6,277 5,809	62.4 56.8 54.9 54.0 48.8
Late and Late Latent Syphilis	1962 1963 1964 1965 1966	78,264 81,736 72,184 67,636 66,149	42.9 44.1 38.4 35.7 34.3	42,536 44,083 38,882 36,578 35,586	47.5 48.8 42.5 39.8 38.0	35,728 37,653 33,302 31,058 30,563	38.5 39.6 34.4 31.9 30.8	37,306 40,042 35,604 31,993 29,905	23.1 24.9 21.4 19.2 17.6	21,324 22,552 19,895 18,133 16,772	26.9 28.2 24.7 22.3 20.3	15,982 17,490 15,709 13,860 13,133	19.5 20.8 18.4 16.2 15.1	40,958 41,694 36,580 35,643 35,643	196.1 192.9 166.2 158.9 157.8	21,212 21,531 18,987 18,445 18,814	209.6 206.5 179.1 170.8 125.1	19,746 20,163 17,593 17,198 17,430	183.4 180.3 154.3 147.9 146.4
Congenital Syphilis	1962 1963 1964 1965	4,085 4,140 3,737 3,505 3,464	2.22 1.9 1.8	1,511 1,497 1,396 1,284 1,345	1.7 1.7 1.5 1.4	2,574 2,574 2,643 2,341 2,21 2,119	2.8 2.8 2.3 2.1	1,943 1,938 1,794 1,647 1,546	1.2 1.2 1.1 1.0 1.0	663 684 644 575 589	80.877	1,280 1.254 1,150 1,072 957	1.00 1.05 1.13 1.13	2,142 2,202 1,943 1,858 1,918	10.3 10.2 8.8 8.3 8.4	848 813 752 709 756	8.4 7.1 5.0 5.0	1,294 1,389 1,191 1,149 1,162	12.0 12.5 10.5 9.9
Gonorrhea	1962 1963 1964 1965 1966	260,468 270,076 290,603 310,155 334,949	142.8 145.7 154.5 163.8 173.6	189,159 2 199,289 2 217,633 2 233,224 2 253,392 2	211.3 220.7 238.1 253.6 270.3	71,309 70,787 72,970 76,931 81,557	76.8 74.5 75.5 82.2	69,475 75,354 81,280 86,055 94,108	43.0 46.0 49.0 51.6 55.3	50,107 55,329 59,056 62,201 67,561	63.1 69.3 73.1 76.6 81.8	19,368 20,025 22,224 23,854 26,547	23.6 23.9 26.1 26.1 30.4	190,993 194,722 209,323 224,100 240,841	914.6 901.1 951.0 999.2 1048.7	139,052 143,960 158,577 171,023 185,831	1374.4 1380.4 1495.6 1583.7 1235.6	51,941 50,762 50,746 53,077 55,010	482.5 454.0 444.8 456.4 462.1

*Includes "Stage of Syphilis Not Stated."

Group 0 - 1 Year	1	1963	1	1964	1	1965	15	1966
	Cases	Percent	Cases	Percent	Cases	Percent	Cases	Percent
	410	6.9	374	10.0	373	10.6	370	10.7
1 - 4 Years	58	1.4	59	1.6	59	1.7	33	1.0
5 - 9 Years	47	1.1	24	0.6	77	1.3	72	2.1
10 Years and Over	3,625	87.6	3,280	87.8	3,029	86.4	2,989	86.2
GRAND TOTAL	4,140	100.0	3,737	100.0	3,505	100.0	3,464	100.0
*Since 1962, approximately 90% of prorated according to known ages.	approximately 90% of co ording to known ages.	congenital cases	have	been reported by ag	age. Cases not	t reported by	/ age have been	ua
			TABLE 6b	6b				
	REPORTE	REPORTED CASES OF CONGE Case Rates Fis	NITA Per UNI cal y	HLLIS, 10 Live ATES 1963-1	UNDER ONE YEAR OF AGE Births** 966	AGE		
1963		1964		I	1965		1966	
Cases Rate	ce Cases	es	Rate	Cases	Rate		Cases	Rate
410 0	0.9 374	4	0.8	373	0.8	~	370	1.0

INFANT MORTALITY DUE TO SYPHILIS - See Table 2.

TABLE 6a

REPORTED CASES OF CONGENITAL SYPHILIS, BY AGE*

	CUMULT TO
TA8LE 7	VU CECONDAUN
	A VOATURA

PRIMARY SYPHILIS WORRENDARY SYPHILIS MORBIDITY AND AGE-SPECIFIC CASE RATES PER 100,000 POPULATION BY AGE GROUPS, COLOR AND SEX

UNITED STATES Calendar Years 1956, 1961 - 1965

AGE		0-14	15-19			20-24		25-29		30-39		40-49		+ 05		Total
YEAR	1956	 1961 1962 1963 1964 1965	1956 1961 1962 1963	1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965
Total	• 2	• • • • • • • • • • • • • • • • • • •	10.7 24.2 24.8 22.8	22.7 24.2	18.4	52.8 55.8 54.8 53.4 52.5	11.3	39.0 40.2 42.8 42.2 41.7	5.7	19.0 19.5 21.7 22.6 22.1	2.3	6.9 7.1 8.1 8.7 8.7	.7	1.5 1.8 1.7 2.0 1.9	3.9	11.0 11.5 11.9 12.1 12.2
ale	.2	. 7 . 6 . 8	11.3 23.8 25.4 24.2	24.5 26.9	11.6	35.5 39.2 38.8 38.7 38.7	6.9	21.4 25.0 27.2 26.8	3.4	8.6 9.7 11.8 13.1 13.5	1.2	3.3 3.4 4.2 4.9	с.		2.8	7.1 7.9 8.4 8.9 9.1
POPULAT	.1		10.1 24.7 24.3 21.4	20.9 21.4	27.0	73.2 75.5 73.8 69.4 68.9	16.1	58.3 57.0 59.6 57.9	8.2	30.3 30.2 32.3 32.9 31.4	3.5	10.6 11.0 12.3 12.7 13.0	1.1	2.4 3.0 3.0 3.0	5.0	15.0 15.2 15.6 15.6 15.6
R 100,000	1.0	2.9 3.0 3.1 3.0	64.2 158.9 169.5 153.2	152.5 164.5	101.1	307.1 346.1 341.1 341.1 342.5 343.9	60.5	215.2 235.7 257.2 267.3 272.2	31.2	96.8 109.5 121.7 135.6 139.8	10.8	33.9 39.1 45.7 51.4 54.3	4.2	7.6 9.5 9.8 12.3 13.1	22.5	63.6 70.6 72.7 76.6 79.3
RATES PER Nonwhite Female	1.7	4.0 4.3 4.8 4.8	68.7 164.0 180.1 168.1	169.9 186.2	72.4	231.8 271.6 264.4 277.1 273.3	43.5	139.7 168.4 183.1 187.5 184.9	22.1	57.1 66.4 79.9 89.2 95.6	6.9	18.3 23.4 28.5 33.6 32.6	2.5	4.1 4.7 6.0 6.8	18.6	49.0 56.9 59.0 62.9 65.1
CASE Male	*4	1.7 1.7 1.6 1.4 1.4	59.3 153.6 158.4 137.6	134.5 142.3	136.1	396.6 435.7 432.0 419.0 426.4	81.1	306.6 316.5 345.8 362.5 375.8	41.8	143.6 160.6 171.5 191.3 192.9	15.1	51.2 56.5 64.9 71.5 79.1	6.0	11.3 14.6 15.3 19.3 20.1	26.7	79.1 85.2 87.5 91.4
ACE-SPECIFIC e Total	0*0	0.0 0.0 0.0 0.0	2.8 5.2 4.7	4.0	6.4	15.9 14.3 14.7 13.0 11.6	5.0	14.7 13.0 13.1 11.1 10.0	2.8	9.2 8.7 7.8 6.6	1.4	6.0.0.0 4.0.0 4.0.0 4.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7	.4		1.6	4.1 3.7 3.8 3.5 3.1
A White Female	0.0	0.0 0.0	2.8 3.8 3.7	3.4 3.4	3.0	6.9 6.0 7.2 5.9	2.0	4.2 5.2 5.2 4.1	1.2	2.1 2.5 2.5 2.6	•5	1.5 1.1 1.5 1.5	. 2	40004	°°	1.5 1.6 1.6 1.6 1.4
Male	0*0	0.0 0.0 0.0	2.8 5.6 5.0	4.6 3.9	10.9	26.5 24.1 23.4 20.3 18.3	8.3	26.0 22.7 21.7 18.8 16.3	4.5	16.7 14.3 15.3 13.4 11.5	2.3	6.2 6.5 6.5 5.6	:7	1.6 1.9 1.8 1.8 1.8	2.4	6.7 6.0 5.5 4.8
Total	78	245 265 273 281	1,163 3,215 3,587 3,438	3,595 4,039	1,758	5,575 6,063 6,332 6,455 6,575	1,263	4,092 4,184 4,518 4,540 4,544	1,358	4,524 4,583 5,026 5,165 4,973	500	1,556 1,621 1,891 2,037 2,055	275	644 764 885 871	6,395	19,851 21,067 22,251 22,969 23,338
Total Female	61	165 191 187 221 201	636 1,611 1,876 1,853	968 259	620	2,028 2,320 2,435 2,600 2,625	405	1,175 1,366 1,531 1,532 1,528	421	1,058 1,189 1,425 1,555 1,574	132	381 402 599 570	67	153 149 153 191 227	2,342 (6,571 19 7,493 21 8,093 22 8,664 22 8,984 2
Male	17	80 74 86 71 80	527 1,604 1,711 1,585	1,627 1,780	1,138	3,547 3,743 3,897 3,855 3,950	858	2,917 2,818 2,987 3,008 3, 0 16	937	3,466 3,394 3,601 3,610 3,399	368	1,175 1,219 1,382 1,440 1,485	208	491 615 620 644	4,053	13,280 13,574 14,158 14,305 14,354
Total	68	231 246 271 271 266	897 2,605 2,993 2,863	3,047 3,505	1,221	4,106 4,707 4,844 5,072 5,303	765	2,735 2,993 3,488 3,588	767	2,586 2,927 3,238 3,583 3,583	231	782 913 1,084 1,325 1,325	126	278 355 375 480 521	4,075	13,323 15,134 15,949 17,179 18,169
MOR&IDITY Nonwhite Female	55	161 177 172 210 193	497 1,373 1,628 1,604	1,730 2,011	482	1,683 2,010 2,036 2,206 2,271	301	972 1,167 1,280 1,331 1,322	291	826 963 1,156 1,284 1,367	78	221 289 429 423	38	78 92 95 143	1,742	5,314 6,326 6,701 7,312 7,730
Male	13	70 69 70 61	400 1,232 1,365 1,259	1,317 1,494	739	2,423 2,697 2,808 2,866 3,032	464	1,763 1,826 2,023 2,157 2,157	476	1,760 1,964 2,082 2,299 2,294	153	561 624 726 809 902	88	200 263 358 378	2,333	8,009 8,808 9,248 9,867 10,439
Total	10	14 19 31 21	266 610 594 575	548 534	537	1,469 1,356 1,488 1,488 1,383 1,272	498	1,357 1,191 1,215 1,052 956	591	1,938 1,656 1,788 1,582 1,312	269	774 708 807 799 730	149	366 409 405 350	2,320	6,528 5,933 6,302 5,790 5,169
White Female	9	4 14 15 11 8	139 238 248 249	238 248	138	345 310 399 354	104	203 199 251 201 206	130	232 226 269 271 207	54	160 113 151 168 147	29	75 58 69 84	600	1,257 1,167 1,392 1,352 1,254
Male	4	10 5 16 10	127 372 346 326	310 286	399	1,124 1,046 1,089 989 918	394	1,154 992 964 851 750	461	1,706 1,430 1,519 1,311 1,105	215	614 595 631 583	120	291 352 340 336 266	1,720	5,271 4,766 4,910 4,438 3,915
YEAR	1956	 1961 1962 1963 1964	1956 1961 1962 1963	1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	 1961 1963 1964 1965	1956	 1961 1963 1964 1965	1956	 1961 1962 1964 1965	1956	1961 1962 1963 1964 1965
AGE		0-14	15-19			20-24		25-29		30-39		40-49		20+		Total

Note: Cases not reported by age have been included on the basis of the known age distribution. Rates are based on population estimates of the Bureau of the Census. Numbers include Alaska and Hawaii for 1956 and 1961-1965. Rates are based on cases excluding Alaska and Hawaii for 1965. For 1961-1965, rates are based on numbers for the United States, including Alaska and Hawaii.

CONORRHEA MORBIDITY AND ACE-SPECIFIC CASE RATES PER 100,000 POPULATION BY ACE CROUPS, COLOR AND SEX

UNITED STATES Calendar Years 1956, 1961 - 1965

ACE		0-14		15~19		20-24		25~29		30-39		40-49		50+		Total
YEAR	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1964 1965	1956	1961 1962 1963 1963 1965
Total	7.1	7.3 6.7 7.8 7.6	415.7	392.7 358.0 361.9 386.2 400.8	781.8	858.6 842.3 853.0 874.7 918.5	434.2	510.3 512.3 517.2 544.8 592.0	171.5	196.7 196.6 205.9 219.3 234.0	41.9	54.9 55.8 61.7 62.3 66.2	7.5	10.3 9.9 10.3 13.0 12.4	135.7	145.8 143.5 149.2 158.8 169.3
Total Female	11.5	10.7 9.6 9.6 10.5 10.0	372.0	312.0 275.8 265.5 283.9 287.4	406.8	428.2 411.2 390.6 381.7 407.5	198.6	224.3 219.5 197.3 204.9 217.1	73.7	76.2 76.8 72.7 78.0 78.0	21.1	21.4 20.9 21.3 20.2 19.8	4.0	4.1 4.0 3.6 4.6	81.7	79.4 76.4 73.7 77.1 80.8
000 POPULATION Tot Male Fema	2.9	3.9 4.0 5.2 5.2	462.9	476.8 444.1 461.5 491.4 515.3	1255.8	1365.8 1357.3 1402.7 1455.0 1523.3	692.6	823.6 835.5 868.3 917.6 1002.0	277.4	326.8 326.8 350.0 371.9 401.9	63.7	90.4 92.9 104.7 107.3 116.0	11.3	17.2 16.5 17.9 22.8 21.5	192.4	215.7 214.5 229.0 245.3 263.1
ER 100, Total	42.7	37.9 36.3 35.8 39.2 39.2	2742.1	2465.0 2245.7 2185.7 2300.2 2377.0	5041.2	5089.5 4949.3 5006.9 5182.9 5377.4	3071.0	3149.4 3056.4 3073.7 3280.5 3538.3	1259.0	1249.1 1213.4 1271.7 1368.8 1444.0	278.7	335.8 344.9 378.6 398.6 431.4	52.9	63.3 61.7 62.9 83.3 75.7	6*066	930.1 893.4 910.6 972.2 1026.0
RATES PER Nonwhite Female T	66.8	52.0 47.7 46.1 49.7 49.9	2430.4	1849.1 1631.3 1469.3 1536.6 1539.6	2714.1	2540.9 2396.5 2254.2 2174.4 22162.0	1372.5	1361.1 1283.0 1155.4 1154.4 1214.0	521.7	478.8 458.0 427.7 466.2 437.4	133.8	124.2 125.0 122.0 114.5 112.4	30.9	27.3 28.8 23.4 23.4 24.7 24.7	600.0	502.0 468.8 436.4 448.9 459.2
IFIC CASE Male	18.7	23.8 25.0 30.8 28.6	3076.0	3107.7 2890.0 2932.7 3096.5 3240.6	7886.2	8117.7 8009.2 8267.8 8691.7 9018.7	5125.7	5314.1 5186.3 5365.8 5781.8 6294.4	2110.3	2157.7 2108.6 2277.8 2451.2 2654.6	439.2	569.6 590.2 666.3 719.0 794.4	76.0	101.9 97.3 106.0 147.6 132.5	1409.5	1388.7 1349.7 1420.7 1535.9 1636.7
AGE-SPECIFIC Total M	1.8	2.3 1.7 2.0 2.2	71.8	100.8 94.9 103.5 109.3 111.8	164.4	245.4 255.2 270.9 273.6 291.9	98.1	146.5 158.5 162.8 167.2 186.7	45.'9	63.5 65.9 67.7 68.8 74.4	15.7	23.2 23.1 25.7 24.0 24.4	3.6	0.0 0.0 4,0 4,0	30.6	43.2 44.4 47.8 49.5 53.2
A White Female	3.0	3.8 3.9 3.6	68.2	95.4 86.6 94.2 101.9 102.4	77.3	120.8 127.5 129.9 133.4 148.6	41.2	59.1 64.8 58.3 63.5 73.9	20.3	22.8 25.5 24.3 24.4 27.8	8.3	9.6 8.8 9.5 8.8	1.7	2.0 1.7 1.8 2.5 2.5	17.4	23.6 24.1 24.9 26.7 26.7 29.0
Male	.6	.8 .6 .8 .8	75.7	106.5 103.5 113.1 117.0 121.3	275.1	392.1 407.7 438.6 439.0 461.8	159.8	241.0 260.8 276.1 279.7 308.8	73.5	106.9 109.4 114.2 116.2 123.8	23.4	37.6 38.1 42.9 39.8 40.9	5.6	9.0 8.7 9.4 10.7 10.7	44.5	63.8 65.9 71.9 73.6 78.7
Total	3,600	4,182 3,881 4,048 4,504 4,525	45,161	52,131 51,679 54,509 61,066 66,947	74,693	90,686 91,591 98,541 105,807 114,945	48,624	53,539 53,5498 54,543 58,623 64,525	40,687	46,772 46,153 47,742 50,072 52,588	9,048	12,463 12,816 14,352 14,655 15,709	2,870	4,385 4,296 4,554 5, 8 39 5,686	224,683	264,158 263,714 278,289 300,666 324,92 5
Total Female	2,851	3,027 2,686 2,760 3,048 2,953	20,938	21,139 20,358 20,334 22,783 24,113	21,724	24,473 24,336 24,504 24,970 27,644	11,660	12,303 11,978 10,887 11,532 12,360	9,120	9,415 9,392 8,759 9,251 9,098	2,334	2,489 2,478 2,555 2,450 2,421	161	933 925 850 1,057 1,124	69,418	73,779 72,153 70,649 75,091 79,713
Male	674	1,155 1,195 1,288 1,556 1,572	24,223	30,992 31,321 34,175 38,283 42,833	52,969	66,213 67,255 74,037 89,837 87,301	36,964	41,236 41,320 43,656 47,091 52,165	31,567	37,357 36,761 38,983 40,821 43,490	6,714	9,974 10,338 11,797 12,205 13,288	2,079	3,452 3,371 3,704 4,782 4,562	155,265	190, 379 191, 561 207, 640 225, 575 245, 212
Total	2,822	3,059 3,015 3,040 3,497 3,486	38,348	40,401 39,659 40,851 45,958 50,654	60,933	68,046 67,314 71,098 76,759 82,920	38,846	40,029 38,819 39,466 42,811 46,635	30,899	33,376 32,434 33,841 36,177 37,818	5,978	7,740 8,057 8,980 9,594 10,523	1,606	2,321 2,313 2,405 3,250 3,011	179,432	194,972 191,611 199,681 218,046 235,047
MORBIDITY Nonwhite Female	2,203	2,097 1,976 1,957 2,159 2,212	17,579	15,477 14,747 14,017 15,643 16,628	18,091	18,447 17,734 17,357 17,308 17,308 18,797	9,512	9,473 8,891 8,076 8,409 8,680	6,869	6,923 6,646 6,189 6,713 6,255	1,507	1,503 1,541 1,531 1,462 1,459	480	517 561 467 509 518	56,241	54,437 52,096 49,594 52,203 54,549
Male	619	962 1,039 1,083 1,338 1,274	20,769	24,924 24,912 26,834 30,315 34,026	42,842	49,599 49,580 53,741 59,451 64,123	29,334	30,556 29,928 31,390 34,402 37,955	24,030	26,453 25,788 27,652 29,464 31,563	4,471	6,237 6,516 7,449 8,132 9,064	1,126	1,804 1,752 1,938 2,741 2,493	123,191	140,535 139,515 150,087 165,843 180,498
Total	778	$1,123\\866\\1,008\\1,107\\1,039$	6,813	11,730 12,020 13,658 15,108 16,293	13,760	22,640 24,277 27,443 29,048 32,025	9,778	13,510 14,479 15,077 15,812 17,890	9,788	13,396 13,719 113,901 113,895 14,770	3,070	4,723 4,759 5,372 5,061 5,186	1,264	2,064 1,983 2,149 2,589 2,675	45,251	69,186 72,103 78,608 82,620 89,878
White Female	648	930 710 803 889 741	3,359	5,662 5,611 6,317 7,140 7,485	3,633	6,026 6,602 7,147 7,662 8,847	2,148	2,830 3,087 2,811 3,123 3,680	2,251	2,492 2,746 2,570 2,538 2,843	827	986 937 1,024 988 962	311	416 364 383 548 606	13,177	19, 342 20, 057 21, 055 22, 888 25, 164
Male	130	193 156 205 218 298	3,454	6,068 6,409 7,341 7,968 8,808	10,127	16,614 17,675 20,296 21,386 23,178	7,630	10,680 11,392 12,266 12,689 14,210	7,537	10,904 10,973 11,331 11,357 11,927	2,243	3,737 3,822 4,348 4,073 4,224	953	1,648 1,619 1,766 2,041 2,069	32,074	49,844 52,046 57,553 59,732 64,714
YEAR	1956	 1961 1963 1964 1965	1956	 1961 1962 1963 1964	1956	 1961 1962 1963 1964	1956	 1961 1962 1963 1964	1956	 1961 1962 1963 1964	1956	 1961 1962 1964 1964	1956	 1961 1962 1964 1964	1956	1961 1962 1963 1964 1965
ACE		0-14		15-19		20-24		25-29		30- 39		40-49		50+		Total

Bureau of the Cenues, Numbers include Alaska and Havail for 1956 and 1961-1965. Rates are based on cases excluding Alaska and Hawail for 1956. For 1961-1965, rates are based on numbers for the United States, including Alaska and Hawaii.

REPORTED VENEREAL DISEASE CASES AND CASE RATES PER 100,000 POPULATION* UNITED STATES (Known Military Cases Excluded) Fiscal Year 1966

			cal Year	1700				
		Syph						her
			Primar	y and			Vene	
State	<u>All Sta</u>	ges	Secon	dary	Gonor	rhea	Disea	ases
	Cases	Rates	Cases	Rates	Cases	Rates_	Cases	Rates
Alabama	1,928	56.1	1,252	36.4	4,056	118.0	45	1.3
Alaska	32	14.6	7	3.2	1,040	470.6	0	-
Arizona	561	35.4	201	12.7	3,158	199.1	10	.6
Arkansas	1,257	64.5	152	7.8	6,064	311.0	11	.7
California	11,726	64.1	1,768	9.7	40,243	220.0	77	.4
Colorado	509	26.4	59	3.1	2,195	113.6	5	.3
Connecticut	644	22.8	103	3.7	2,762	97.9	3	.1
Delaware	517	104.0	46	9.3	1,100	221.3	3	.6
Dist. of Columbia	1,473	186.7	468	59.3		1259.9	381	48.3
Florida	6,320	110.6	2,103	36.8	10,619	185.9	265	4.6
Georgia	2,526	59.2	1,014	23.8	12,149	285.0	117	2.7
Hawaii	130	20.1	35	5.4	402	62.0	5	.8
Idaho	130	2.4	9	1.3	1,049	152.9	2	.3
Illinois	7,188	67.8	1,260	11.9	31,153	294.0	12	.1
Indiana	1,075	22.0	76	1.6	4,540	93.1	4	.1
Iowa	851	30.9	70	2.6	2,873	104.2	5	.1
Kansas	977	44.5	62	2.0	2,875	127.5	2	.1
		54.8	125			110.0	16	.1
Kentucky	1,723			4.0	3,455 5,509		63	1.8
Louisiana	2,869	81.8	649	18.5		157.4		
Maine	279	28.6	4	.4	402	41.2	0	-
Maryland	3,243	93.7	555	16.0	6,741	194.7	13	.4
Massachusetts	1,787	33.6	331	6.2	4,401	82.9	5	.1
Michigan	5,784	70.7	1,057	12.9	14,765	180.1	130	1.5
Minnesota	204	5.8	56	1.6	2,187	61.6	2	.1
Mississippi	951	41.3	647	28.1	4,401	191.3	35	1.5
Missouri	3,503	78.4	214	4.8	8,622	192.9	54	1.2
Montana	145	20.8	35	5.0	473	68.0	2	. 2
Nebraska	373	25.6	78	5.3	1,080	74.0	1	.1
Nevada	231	53.5	32	7.4	687	159.0	1	.2
New Hampshire	79	11.9	14	2.1	296	44.7	5	.8
New Jersey	3,943	58.5	828	12.3	4,016	59.6	13	.1
New Mexico	942	93.5	101	10.0	1,567	155.6	2	.2
New York	18,866	104.7	3,329	18.5	37,889	210.2	98	.5
North Carolina	2,242	46.5	976	20.2	10,318	214.0	87	1.8
North Dakota	19	3.1	5	.8	442	69.1	0	-
Ohio	4,277	41.9	623	6.1	14,527	142.1	26	.3
Oklahoma	1,204	49.3	110	4.5	3,446	140.8	8	.3
Oregon	362	19.2	55	2.9	2,532	133.7	3	. 2
Pennsylvania	4,961	43.1	567	4.9	8,790	76.4	23	. 2
Rhode Island	348	38.9	31	3.5	359	40.1	0	-
South Carolina	1,742	70.0	882	35.5	7,121	286.2	22	.8
South Dakota	115	16.5	36	5.2	659	94.7	1	.1
Tennessee	1,389	36.4	342	9.0	9,962	261.1	36	1.0
Texas	5,528	53.2	1,544	14.9	28,560	275.0	105	1.0
Utah	139	14.1	18	1.8	427	43.4	0	-
Vermont	21	5.3	2	.5	208	52.4	2	.5
Virginia	1,972	45.9	296	6.9	8,060	187.7	28	.7
Washington	251	8.6	48	1.6	3,449	117.8	5	.2
West Virginia	1,436	79.2	100	5.5	934	51.6	3	.2
Wisconsin	1,368	33.1	89	2.1	2,362	57.1	3	.1
Wyoming	101	30.2	7	2.1	160	47.8	0	-
United States Total	110,128	57.1	22,473	11.6	334,949	173.6	1,739	.9

*Rates less than .05 not shown.

Health Department Casefinding Activities

Casefinding investigations fall into two categories: (1) the investigation of sex contacts of patients with recently acquired and infectious disease, and (2) the investigation of persons other than sex contacts who are suspected of having venereal disease. Most of the latter group of suspects are persons with reactive tests for syphilis which are generated by the estimated 38,000,000 serologic tests performed annually in the United States, and are referred to in Table 10 as positive diagnostics. Thousands of the investigations of positive diagnostics and sex contacts carry health department casefinding workers into the offices of private physicians who make the medical determination of whether or not the suspects have syphilis.

For many years, the proficiency of the interviewing-contact investigation process in ferreting out the foci of syphilis infections in the community has been measured by a series of epidemiologic indices. The indices presented in Table 10 are based only on infectious cases diagnosed in health department clinics and do not include cases diagnosed and reported by private physicians. These indices are defined as follows:

The <u>Contact Index</u> is the average number of sex contacts elicited per infectious (primary and secondary) syphilis case interviewed.

The <u>Epidemiologic Index</u> is the average number of cases of syphilis identified per infectious case interviewed. A number of these identified cases will already have been diagnosed and treated.

The <u>Brought-to-Treatment Index</u> is the average number of previously not diagnosed cases of syphilis brought to treatment per infectious case interviewed.

The <u>Lesion-to-Lesion Index</u> is the average number of infectious (lesion or primary or secondary) cases brought to treatment per infectious case interviewed.

	·					
	1961	1962	1963	1964	1965	1966
Number of positive diag-						
nostics investigated.	239,835	234,305	243,257	241,016	245 ,7 15	25 7, 009
Number of contacts in- vestigated.	225,541	186,784	179,715	192,580	186,386	183,634
Contact Investigation Indices:						
Contact Index	4.10	4.03	3.98	3.86	3.69	3.59
Epidemiologic Index	1.22	1.24	1.17*	1.13*	1.11*	1.13*
Brought-to-Treatment Index	•55	.52	. 4 7 *	.46*	•45 *	.45*
Lesion-to-Lesion Index	.33	.32	.30	.31	.32	.30

TABLE 10 HEALTH DEPARTMENT CASEFINDING ACTIVITIES, UNITED STATES FISCAL YEARS 1961-1966

*Excludes Missouri, South Carolina, and Tennessee.

Treatment of Syphilis

Congenital Syphilis

Recommended treatment for early congenital syphilis (less than 2 years) consists of aqueous procaine penicillin G in total dosage of $100,000 \mu/\text{kg}$. in 10 equally divided daily doses. Late congenital syphilis is treated with the same schedules as for comparable manifestations of acquired syphilis.

The earlier penicillin therapy is instituted for congenital syphilis, the more satisfactory the results.

Early Syphilis

Benzathine penicillin G and procaine penicillin G in oil with 2-percent aluminum monostearate (PAM) are the most widely used penicillin preparations for the treatment of early syphilis. Since benzathine penicillin G maintains a detectable blood level for a much longer period of time than PAM, a smaller total dosage is required for satisfactory results. The recommended schedules are 2,400,000 units of benzathine penicillin G administered in a single session (1,200,000 units in each buttock) or 4,800,000 units of PAM, 2,400,000 units at first session, and subsequent injections of 1,200,000 units given at 2- or 3-day intervals. If aqueous procaine penicillin G is used, 600,000 units should be administered daily for 8 days to total 4,800,000 units.

For the patient who is sensitive to penicillin, erythromycin (20-30 grams) or tetracycline (30-40 grams) is recommended for the treatment of syphilis.

Epidemiologic Treatment

The treatment of all sex contacts of patients with early infectious syphilis is recommended as the most effective procedure for preventing the spread of syphilis. Although clinically and serologically negative at time of initial examination, some of these contacts will have incubating syphilis and some, particularly females who may have an inconspicuous or no primary lesion, will already have developed syphilis. It is suggested, therefore, that contacts be treated for syphilis (rather than for incubating syphilis) with a dosage of 2,400,000 units of benzathine penicillin G.

Syphilis in Pregnancy

Congenital syphilis is completely preventable. Adequate treatment of the mother during the first 18 weeks of gestation prevents infection of the baby; adequate treatment after the 18th week cures the baby in utero.

In two studies, comprising 528 infants born to treated syphilitic mothers, approximately 98 percent of the children were nonsyphilitic. The percentage varied slightly by stage of mother's syphilis during pregnancy.

In the absence of relapse or reinfection, a woman treated with penicillin for syphilis will not require further treatment in the event of pregnancy.

Neurosyphilis

A cooperative study conducted by the Public Health Service and leading neurosyphilologists in the United States has demonstrated that penicillin is the most effective treatment yet known for neurosyphilis.

Asymptomatic Neurosyphilis — Among 765 patients with asymptomatic neurosyphilis, approximately 75 percent of whom were treated with a minimum of 4,800,000 units of penicillin, only one bona fide progression to symptomatic neurosyphilis was observed; 11 other patients exhibited minor neurologic changes. In contrast, among 467 patients treated with metal chemotherapy, 29 progressed to symptomatic neurosyphilis and an additional 15 showed minor neurologic changes.

Paresis — Six hundred and twenty-nine patients were treated for paresis with penicillin only, 60 percent of whom received a minimum of 6,000,000 units. Paresis was diagnosed severe in 330, moderately severe in 141, and mild in 158. Five years after treatment 42 percent of those with severe psychoses were in remission or showed significant improvement, 45 percent remained unchanged, and only 13 percent had progressed or died from paresis. Progression or death from paresis occurred in 7.0 percent of those with moderately severe psychosis and in less than one percent of those with mild psychosis. Further proof of the effectiveness of penicillin is the fact that among those who survived, one-third of those who had been institutionalized, and two-thirds of those who had been unable to work at time of treatment were gainfully employed 5 years later.

The total recommended dosage of penicillin for both symptomatic and asymptomatic neurosyphilis is 6,000,000 to 9,000,000 units. Any benefit from more than 10,000,000 units is doubtful and has not been demonstrated. Treatment schedules are as follows:

Benzathine penicillin G — 3,000,000 units at 7-day intervals. PAM — 1,200,000 units at 3-day intervals. Aqueous procaine penicillin G — 600,000 units daily.

Treatment of Gonorrhea

The treatment of gonorrhea is in a state of uncertainty although penicillin still remains the drug of choice. Some strains of the gonococcus are developing increasing resistance to penicillin, but this resistance is relative and not absolute. As a result it is necessary to recommend on an interim basis short acting penicillin preparations in larger doses. Treatment schedules are presently being evaluated and until results are available the following are recommended:

Uncomplicated gonorrhea in men: Aqueous procaine penicillin G, 2,400,000 units in one IM injection.

Uncomplicated gonorrhea in women: Aqueous procaine penicillin G, 4,800,000 units IM in two injection sites at one visit, or the combination of aqueous procaine penicillin G and procaine penicillin G in oil with 2 percent aluminum monostearate for two separate IM injections of 2,400,000 units in each site given at one visit. Prophylactic or epidemiologic treatment for gonorrhea (male and female) is accomplished with the same treatment schedules as for uncomplicated gonorrhea.

Treatment of gonorrhea with severe complications must be individualized using large amounts of short acting penicillin.

Excluding the likelihood of reinfection, retreatment is indicated if the discharge in uncomplicated male gonorrhea persists for three or more days following initial therapy and the smear, F.A., or culture is still positive. In uncomplicated gonorrhea in the female retreatment is indicated if followup cultures or F.A. procedures remain positive for gonococci. Retreatment consists of doubling the original dosage at a single visit or in divided doses on two successive days.

Gonorrhea patients sensitive to penicillin may be treated effectively with tetracycline, erythromycin, or oleandomycin. These may be administered as a single oral dose of 1.5 grams or 0.5 gram given orally every 4-6 hours until 2-3 grams have been given.

Gonorrhea patients who are sexual contacts to infectious syphilis should be given full prophylactic therapy for syphilis (2,400,000 units of benzathine penicillin G) as well as recommended therapy for gonorrhea. While long acting forms of penicillin (such as benzathine penicillin) are ideal in syphilotherapy, they are not indicated in routine gonorrhea treatment.

Penicillin Reactions

Since penicillin is the drug of choice for the treatment of both syphilis and gonorrhea, the Venereal Disease Program is concerned with the frequency and severity of reactions to penicillin therapy. Through the cooperation of venereal disease clinics three studies at 5-year intervals (1954, 1959 and 1964) have been conducted to determine their frequency.

The 1959 and 1964 studies were patterned after the 1954 study, the single departure being a request that, if possible, patients be detained in the clinic for a 30-minute period following treatment. Reactions to penicillin were reported in 5.9/1,000 patients treated in 1954, in 9.7/1,000 treated in 1959, and in 8.0/1,000 treated in 1964. The increase over 1954 is attributed mainly to the delay in dismissing patients after treatment.

In each study, urticaria was the most frequent type of reaction, occurring in from 4-6/1,000 patients treated. Moderate to severe anaphylaxis was observed in 0.21 to 0.35/1,000 patients. The only death reported during a study period occurred in 1964.